Division of Breast and Endocrine Surgery, Department of Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan.
Anticancer Res. 2011 Nov;31(11):3839-42.
A disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS1), a member of the ADAMTS family of proteases, is involved in the shedding of epidermal growth factor (EGF)-like ligands such as amphiregulin, which activate the EGF receptor. Since ADAMTS1 has been implicated in aggressive breast carcinogenesis, we examined potential antitumor effects of antibody to ADAMTS1 in a mouse model of breast cancer.
BALB/c female mice were inoculated with syngenic 4T1 breast cancer cells and treated with anti-ADAMTS1 antibody or control IgG. Tumor volume and weight were evaluated.
Mouse 4T1 cells expressed ADAMTS1 and its substrates amphiregulin and heparin-binding EGF. Treatment with antibody to ADAMTS1 inhibited tumor growth without any adverse effects.
ADAMTS1 could be a promising molecular target for immunotherapy of breast cancer.
解整合素金属蛋白酶 13（ADAMTS1）是 ADAMTS 蛋白酶家族的成员，参与表皮生长因子（EGF）样配体如 Amphiregulin 的脱落，这些配体激活 EGF 受体。由于 ADAMTS1 与侵袭性乳腺癌的发生有关，我们在乳腺癌小鼠模型中研究了抗 ADAMTS1 抗体的潜在抗肿瘤作用。
BALB/c 雌性小鼠接种同源 4T1 乳腺癌细胞，并接受抗 ADAMTS1 抗体或对照 IgG 治疗。评估肿瘤体积和重量。
小鼠 4T1 细胞表达 ADAMTS1 及其底物 Amphiregulin 和肝素结合 EGF。用抗 ADAMTS1 抗体治疗可抑制肿瘤生长，无任何不良反应。
ADAMTS1 可能成为乳腺癌免疫治疗的有前途的分子靶点。
